Condition
HIV-1 clinical trials and research
As of November 12, 2026, Find a Trial lists 5 HIV-1 clinical trials that are recruiting, at sites in 10 countries (most in United States (2), Argentina (1), France (1)). By phase: Phase 1 (2), Phase 4 (1), Early Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 10Countries
Newest HIV-1 clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Blocking BCL-2 when starting HIV treatment to help infected cells die (INITIATE) | Phase 1 | Aarhus and 1 other locations | Recruiting | Mar 18, 2026 |
| Switching to once-daily dolutegravir plus lamivudine for transgender women with HIV | Phase 4 | Buenos Aires, Buenos Aires F.D. | Recruiting | May 13, 2025 |
| Safety and dosing of two long‑lasting HIV antibodies in newborns | Phase 1 | Los Angeles, California and 18 other locations | Recruiting | Jul 24, 2024 |
| Impact of Viral Infections on Blood Cell Development | — | Boulogne-Billancourt | Recruiting | Jun 13, 2024 |
| Using CMV-specific T cells to treat HIV/AIDS | Early Phase 1 | Duarte, California and 1 other locations | Recruiting | Feb 9, 2024 |
All recruiting trials (5)
-
Blocking BCL-2 when starting HIV treatment to help infected cells die (INITIATE)
This trial will try giving the BCL-2 blocker venetoclax to people with newly diagnosed HIV who are starting ART to see if it helps infected cells die and reduces the hidden HIV reservoir.
-
Switching to once-daily dolutegravir plus lamivudine for transgender women with HIV
This will test whether switching to once-daily dolutegravir plus lamivudine keeps HIV suppressed and is safe for transgender women already on suppressive antiretroviral therapy.
-
Safety and dosing of two long‑lasting HIV antibodies in newborns
This will try giving one or two long‑lasting HIV antibodies soon after birth to infants born to people with HIV to check safety and how long the antibodies stay in the baby's blood.
-
Impact of Viral Infections on Blood Cell Development
This study is trying to see how HIV and COVID-19 affect the development of blood cells in both healthy people and those with HIV by looking at their bone marrow.
-
Using CMV-specific T cells to treat HIV/AIDS
This study is testing a new treatment using specially designed T cells to see if they can help people with HIV live better while they are on their regular medication.
Related topics
Quick answers
How many HIV-1 clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 10 countries. The most sites are in United States (2 trials), Argentina (1 trial), France (1 trial), Denmark (1 trial), Spain (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 4: 1, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.